A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
Hoosier Cancer Research Network
Hoosier Cancer Research Network
Memorial Sloan Kettering Cancer Center
University of Oklahoma
Regeneron Pharmaceuticals
Bolt Biotherapeutics, Inc.
Regeneron Pharmaceuticals
Jules Bordet Institute
SillaJen, Inc.